Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker
- Resource Type
- article
- Authors
- Mônica M. C. Becker; Gustavo F. A. Arruda; Diego R. F. Berenguer; Roberto O. Buril; Daniela Cardinale; Simone C. S. Brandão
- Source
- Cardio-Oncology, Vol 9, Iss 1, Pp 1-13 (2023)
- Subject
- Cardiotoxicity
18F-FDG PET/CT
Anthracyclines
Nuclear medicine
Early diagnosis
Cardio-oncology
Diseases of the circulatory (Cardiovascular) system
RC666-701
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 2057-3804
Highlights ∙ CTX related to chemotherapy is an important cause of heart failure in surviving cancer patients; ∙ Cardiomyocytes may increase their glycolytic metabolism under significant stress. This phenomenon has been observed in both experimental and clinical studies; ∙ PET/CT is a powerful noninvasive diagnostic technique that provides both anatomical and metabolic information; ∙ 18F-FDG is a glucose analog that is the most commonly used radiopharmaceutical in oncological PET/CT exams; ∙ The degree of myocardial 18F-FDG uptake may be a promising marker of the cardiomyocyte changes that precede cardiac dysfunction in the CTX cascade.